Edition:
United Kingdom

Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

0.71USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
156,488
52-wk High
$5.02
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Immune Pharmaceuticals reports Q3 results
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update.Immune Pharmaceuticals Inc - ‍Company recorded no revenue for three-month periods ended September 30, 2017 and 2016​.  Full Article

Immune Pharmac prices $18 mln public offering
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals Inc announces pricing of $18,000,000 public offering of convertible preferred stock and warrants.Immune Pharmaceuticals Inc - ‍offering will be comprised of units, priced at a public offering price of $1,000 per unit​.  Full Article

Immune Pharmaceuticals Q2 loss per share $0.13
Tuesday, 16 Aug 2016 

Immune Pharmaceuticals Inc : Q2 loss per share $0.13 .Immune Pharmaceuticals provides business and research and development update and announces second quarter 2016 financial results.  Full Article

Immune Pharmaceuticals offers up to 3.2 mln shares
Friday, 29 Jul 2016 

Immune Pharmaceuticals Inc :Says it is offering up to 3.2 million shares of co's common stock to institutional investors - SEC filing.  Full Article

Immune pharmaceuticals to form pain,neurology spin off company around AmiKet
Tuesday, 19 Jul 2016 

Immune Pharmaceuticals Inc : Immune pharmaceuticals to form pain and neurology spin off company around AmiKet . Says parties have agreed to a target closing date of september 15, 2016 . NPT plans to make first tranche of its investment into new subsidiary upon closing based on pre-agreed terms . Parties have agreed to a target closing date of september 15, 2016 . According to amended agreement immune will form a pain-neurology subsidiary, which will own AmiKet intellectual property .Says entered into an amended agreement with NPT, a syndicate of experienced healthcare investors.  Full Article

Immune Pharma expands bertilimumab mid-stage clinical trial in bullous pemphigoid
Tuesday, 14 Jun 2016 

Immune Pharmaceuticals Inc : Six academic clinical sites in united states for its bp-01 study are anticipated to be initiated over this summer .Immune pharmaceuticals expands its bertilimumab phase ii clinical trial in bullous pemphigoid to six academic institutions in the united states.  Full Article

Immune Pharmaceuticals and Hadasit file a joint patent on oral use of anti-Eotaxin Monoclonal antibodies, including Bertilimumab
Wednesday, 8 Jun 2016 

:Immune Pharmaceuticals and Hadasit file a joint patent on oral use of anti-Eotaxin Monoclonal antibodies, including Bertilimumab.  Full Article

Immune Pharma Q1 loss per share $0.17
Monday, 16 May 2016 

Immune Pharmaceuticals Inc : Immune pharmaceuticals provides business and research and development update and announces first quarter 2016 financial results .Q1 loss per share $0.17.  Full Article

Immune Pharmaceuticals posts new data with topical cyclosporine nano-capsules
Monday, 4 Jan 2016 

Immune Pharmaceuticals:Posts new data with topical cyclosporine nano-capsules.Intend to accelerate the development of product candidate under the abbreviated 505(b)(2) drug development pathway.Says acquires worldwide rights and accelerates development for the treatment of psoriasis and atopic dermatitis.Says entered into an exclusive worldwide licensing and development agreement with bionanosim ltd for cyclosporine.Says will fund further development of product candidate and bionanosim will be eligible to potentially milestone payments.  Full Article

BRIEF-Immune Pharmaceuticals reports Q3 results

* Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update